ArticleCureus2025
Severe Withdrawal Symptoms and Pseudohyperchloremia Induced by Bromvalerylurea: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromvalerylurea is a sedative-hypnotic agent commonly available in over-the-counter (OTC) medications in Japan and other regions. Although widely used, its prolonged and unsupervised use poses significant risks of dependency and withdrawal. Abrupt discontinuation of bromvalerylurea can lead to severe withdrawal symptoms, including agitation, hallucinations, and seizures. However, standardized management protocols for bromvalerylurea withdrawal have not been established. A 19-year-old male with a suspected history of attention deficit hyperactivity disorder presented with severe agitation, hallucinations, and a generalized tonic-clonic seizure after abruptly discontinuing the sedative containing bromvalerylurea. He had been using an OTC sedative for nine months, progressively increasing his daily intake from three to 24 tablets. Upon admission, his vital signs were stable, but his serum chloride levels exceeded the measurable upper limit due to pseudohyperchloremia caused by bromide, a metabolite of bromvalerylurea. Initial management included oral diazepam 5 mg three times daily, which was tapered over nine days, leading to a resolution of withdrawal symptoms and normalization of chloride levels. The patient was transferred to a psychiatric facility on day 17 for substance use disorder treatment. Drug assays revealed undetectable bromvalerylurea levels by admission, while allylisopropylacetylurea levels declined by day 8. This case underscores the severe withdrawal risks associated with bromvalerylurea, demonstrating the effectiveness of diazepam in stabilizing symptoms during withdrawal. Additionally, pseudohyperchloremia caused by bromide metabolism highlights the importance of recognizing this laboratory finding to avoid unnecessary interventions. With bromvalerylurea products being phased out as OTC medications due to safety concerns, efforts must focus on raising awareness about their risks and preventing misuse through online sales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.